Sweet spot found for LDL-C reduction to minimize risk




Researchers have identified a “sweet spot” target for reducing low-density lipoprotein cholesterol levels with statin therapy that is associated with the lowest risk of adverse cardiac outcomes.

A study published online June 20 in JAMA Internal Medicine analyzed data from an Israeli health care organization between 2009-2013 and identified 31,619 patients with ischemic heart disease, aged 30-84 years, who were being treated with statins and were at least 80% adherent to the medication regime.

Louise Koenig/Frontline Medical News

The analysis showed individuals who achieved a “moderate” LDL-C level – between 70.1-100.0 mg/dL – after 1 year of statin treatment had an 11% lower incidence of major adverse cardiac events, compared with those with a “high” LDL-C level – between 100.1-130.0 mg/dL (95% confidence interval, 0.84-0.94; P less than .001).

However researchers observed no significant difference in the risk of adverse cardiac events between the moderate group and those who achieved a “low” LDL-C equal to or less than 70.0mg/dL (hazard ratio, 1.02; 95% CI, 0.97-1.07; P = .54).

In a further analysis that included 54,884 individuals who were at least 50% adherent to their statin therapy, there was a slightly increased risk of major cardiac events in patients who achieved a low LDL-C, compared with those in the moderate LDL-C group, and a significant 13% reduction in risk in the moderate LDL-C group, compared with the high LDL-C group.

“Whereas this may reflect clinical risk of low levels of LDL-C, these results further support the main findings of this study that achieving a level below 70 mg/dL is not beneficial for all patients,” wrote Dr. Morton Leibowitz, from the Clalit Research Institute, Tel Aviv, and his coauthors.

Adjustment for age did not significantly alter the interaction between LDL-C levels and the risk of adverse cardiac events (JAMA Intern Med. 2016 Jun 20. doi: 10.1001/jamainternmed.2016.2751).

“The question of the association between achieved LDL-C levels and major adverse cardiac events for secondary prevention has become highly relevant, particularly in the real-world context of patients excluded from [randomized, controlled trials],” the authors wrote, suggesting that their data only partially support recent claims that lower LDL-C is better for cardiac outcomes.

“Our findings of significantly lower risk of MACEs associated with achieved LDL-C level of less than 100.0 mg/dL but not with achieved LDL-C of less than 70.0 mg/dL suggest a target for long-term statin treatment.”

The study was funded by the Clalit Research Institute. No conflicts of interest were reported.

Recommended Reading

Gas-filled gastric balloons achieve weight loss
MDedge Cardiology
Statins, but not aspirin, linked to lower pancreatic cancer risk
MDedge Cardiology
Obesity paradox extends to TAVR but not SAVR
MDedge Cardiology
Obesity continues to trend up among women over the past decade
MDedge Cardiology
Adolescent obesity rose slightly, again
MDedge Cardiology
Phentermine-topiramate shows best chance of weight loss at 1 year
MDedge Cardiology
Long-acting opioids increase cardiovascular deaths in noncancer patients
MDedge Cardiology
Simplify cardiac risk assessment for rheumatologic conditions
MDedge Cardiology
FDA strengthens kidney warnings on two diabetes drugs
MDedge Cardiology
Empagliflozin slows renal disease progression in type 2 diabetes
MDedge Cardiology